Navigation Links
Northfield Laboratories Investor Update

EVANSTON, Ill.--(BUSINESS WIRE)--Apr 26, 2007 - Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that its contract research organization has informed the Company that the report of the summary data from its pivotal Phase III trauma trial with PolyHeme(R), the Company's human-hemoglobin based oxygen-carrying red cell substitute, will not be complete until May.

About Northfield Laboratories

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme(R) is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com.

Forward Looking Statement

This press release may contain forward-looking statements concerning, among other things, Northfield's future business plans and strategies and clinical and regulatory developments affecting our PolyHeme red blood cell substitute product. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including the possibility that the final data from our Phase III clinical trial, once available, may not be sufficient to demonstrate the safety or effectiveness of PolyHeme, our ability to obtain FDA approval to market PolyHeme commercially, our ability to obtain Fast Track designation and priority review, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain ade
'"/>




Page: 1 2

Related medicine technology :

1. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
6. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
7. Acorda Therapeutics to Host Analyst and Investor Reception
8. Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Avexas Apricitabine Clinical Trial Update
11. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Northfield Laboratories Investor Update
(Date:5/4/2015)... TORONTO , May 4, 2015 ... that it intends to dividend to its stockholders a ... a definitive licensing agreement to license its RapidMist™ buccal ... (OTCQB:SMFI). As announced on April 23, 2015, ... respect of the licensing of its RapidMist™ buccal drug ...
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have ... live video and product demonstrations at the end of ... equipment such as Kodak and Fuji Cr,s, Agfa and ... at the first event. Various imaging equipment will be ... . After years of buying and selling ...
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
... CITY, Minn., Dec. 21 William Fals-Stewart,Ph.D., professor in ... in,Rochester, New York, has earned the 2007 Dan Anderson ... partner involvement in the,treatment of female alcoholics. Sponsored by ... a single published article by a researcher,who has advanced ...
... Dec. 20 Novavax, Inc.,(Nasdaq: NVAX ) ... I/IIa,human clinical trial of its non-adjuvanted pandemic influenza ... Chief Medical Officer and Head of Clinical,Development stated, ... are,promising and support further development of our pandemic ...
Cached Medicine Technology:Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 2Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 3Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 4Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4
(Date:5/4/2015)... 04, 2015 Malibu Biotech Systems ... breath spray. KissSafe™ is the first personal hygiene ... experience while adding fresh breath appeal. KissSafe™ contains ... kills germs in the mouth and oral cavity ... ingredients that possess additional wellness benefits. KissSafe’s proprietary ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... The opportunity for children to dream of a bright ... behind The Fairy Godmother Next Door, a new children’s picture ... , The inspiration for the enchanting story of a fairy ... desire to be a fairy godmother. , “My wish came ... neighbors’ children since they were born. We discuss fairies and ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... behaviors, study says , , THURSDAY, Nov. 6 (HealthDay News) ... much lower in areas that have lots of green ... large British study finds. , Dr. Richard Mitchell, of ... previous studies have shown that the presence of green ...
... Calif., Nov. 6 Lumenis(R) Ltd. a global,developer, ... for ophthalmic, surgical and aesthetic applications,announced today that ... devices on November 8th at the American Academy ... Dov Ofer, Lumenis, President and Chief Executive Officer ...
... of veterans with posttraumatic stress disorder (PTSD) raises the ... and children in communities across the United States," says ... and an assistant professor of social work at Washington ... are very different than those for PTSD. The Department ...
... Texas, Nov. 6 The following was released ... A recent report from the U.S. Department of ... 08-01105-171) substantiated waste,mismanagement and inaction to disclosures of ... Central Texas Veterans Health,Care System (CTVHCS)., Inaction ...
... 6 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... Officer of Savient Pharmaceuticals,will present a corporate update ... The presentation is scheduled to begin on November ... The Conference will be held at the Arizona,Biltmore ...
... 6 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... anti-infective products, today,announced that three patents protecting Moxatag ... Orange Book on,Oct. 24, 2008, pursuant to Section ... on Oct. 8, 2008., MiddleBrook President & ...
Cached Medicine News:Health News:Green Areas Lower Health Inequities Between Rich, Poor 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 3Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 4Health News:Growing problem for veterans: Domestic violence 2Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: